Brought to you by:
Endospan announces positive 30-day outcomes from TRIOMPHE IDE study
Endospan recently announced the presentation of 30-day results from the statistical dissection primary arm of the TRIOMPHE investigational device exemption (IDE) clinical study. The data were presented during the late-breaking trial session at the American Association for Thoracic Surgery (AATS)…
VVT Medical welcomes Antonios Gasparis to medical advisory board
VVT Medical recently announced the appointment of Antonios Gasparis, MD, to its medical advisory board. A press release notes that Gasparis brings over two decades of expertise in vascular surgery, with a distinguished career dedicated to advancing the treatment of…
Inquis Medical’s Aventus thrombectomy system found safe and effective for patients with PE
Inquis Medical recently announced results from its AVENTUS trial evaluating the safety and efficacy of the company’s Aventus thrombectomy system. The results were presented by Jun Li, MD, from University Hospitals Harrington Heart & Vascular Institute in Cleveland, the trial’s…
New study validates BEST-CLI trial results, ‘suggesting generalizability’
A new propensity-matched analysis of more than 1,100 lower extremity revascularization procedures carried out in patients with chronic limb-threatening ischemia (CLTI)—which aimed to help solve the puzzle of why the BEST-CLI trial did not lead to a pick-up in the…
‘The leader must own everything in his or her world, own every mistake and credit the team for successes’
“We can almost be considered a specialty of colonizers, acquiring borrowed techniques. Why, then, do we see ourselves as the keepers of vascular care? Why do we think that we are the ones that can deliver the best vascular care?…
Debate verdict: Carotid endarterectomy maintains its golden hue
The established “gold-standard” approach to carotid revascularization remained enshrined as the go-to operation as far as a 2025 Charing Cross (CX) International Symposium audience was concerned. Some 76% of those who voted in the post-debate poll sided with Barbara Rantner,…
R3 Vascular announces first patient treated in ELITE-BTK pivotal trial
R3 Vascular recently announced that the first patient in its ELITE-BTK pivotal trial has been treated by Brian DeRubertis, chief of vascular surgery at New York-Presbyterian and Weill Cornell Medicine in New York City. The trial evaluates R3 Vascular’s next-generation…
CX 2025: New VenaSeal data suggest cyanoacrylate closure be added to the venous “toolkit”
Twelve-month outcomes of the VenaSeal Spectrum venous leg ulcer (VLU) trial, assessing time to ulcer healing following treatment with the VenaSeal (Medtronic) closure system, have demonstrated an 81.3% ulcer healing rate at one year. Manj Gohel (Cambridge, United Kingdom) presented…
CX 2025: Sirolimus implant fails to meet fistula maturation endpoint in ACCESS 2 trial
Results of the ACCESS 2 study, evaluating arteriovenous fistula (AVF) outcomes following use of the Sirogen (Vascular Therapies) sirolimus-eluting collagen implant, have shown that the device failed to meet non-inferiority for clinical fistula maturation compared to control at six months.…
CX 2025: EVAR founding fathers invoke revolutionary past to predict path ahead for aortic stent graft development
The next spring forward in aortic stent grafting will be rooted in a greater understanding of the biomechanical forces acting upon devices alongside continued advances and specialization in imaging, according to some of the founding fathers of endovascular aneurysm repair…